RXRX vs. SDGR: Which AI-Powered Drug Discovery Stock Has More Upside?

An article comparing Recursion Pharmaceuticals (RXRX) and Schrodinger (SDGR), two AI-driven drug discovery companies, suggests RXRX is currently a more attractive investment. While both face competition and pipeline risks, RXRX's narrowing loss estimates, encouraging collaboration agreements (including $7M recently from Sanofi), and cheaper valuation make it a better bargain, despite a 39.6% year-to-date stock decline compared to SDGR's 10.9% gain; SDGR's widening loss estimates and higher valuation suggest potential downside.

Analysis

Recursion Pharmaceuticals (RXRX) and Schrodinger (SDGR) are both leveraging artificial intelligence to innovate within the drug discovery sector, aiming to reduce costs and timelines associated with traditional biotech R&D. RXRX recently executed a strategic pipeline reprioritization, discontinuing development of its lead candidate REC-994 and two other programs following unfavorable mid-stage results, but subsequently reported encouraging preliminary Phase II data for REC-4881 in familial adenomatous polyposis, which demonstrated a median 43% reduction in polyp burden by week 13, with additional data expected in the second half of 2025. The company ended Q1 2025 with a cash balance of $509 million, projected to fund operations into mid-2027, and recognized $15 million in collaboration revenues in the quarter, slightly up year-over-year, further bolstered by a recent $7 million milestone payment from Sanofi. Despite a significant 39.6% year-to-date decline in its stock price, RXRX's consensus loss per share estimates for 2025 have narrowed, implying a 21% year-over-year improvement, and the stock trades at a price-to-book ratio of 1.78, which is considerably below its five-year mean of 3.64. In contrast, Schrodinger's clinical pipeline is at an earlier stage, with initial Phase I data for its lead candidate SGR-1505 in B-cell malignancies anticipated in June 2025. SDGR reported strong Q1 2025 financial results, with total revenues increasing 63% year-over-year to $59.6 million, primarily driven by a 46% growth in software revenues to $48.8 million and a 234% surge in drug discovery revenues to $10.7 million. However, SDGR's stock has appreciated 10.9% year-to-date, its consensus loss per share for 2025 is expected to widen by 2%, and it trades at a higher price-to-book ratio of 4.2, surpassing its five-year mean of 4.09. While both companies are rated Zacks Rank #3 (Hold) and face inherent sector-specific risks such as early-stage pipelines and intense competition, the comparative analysis suggests RXRX presents a more favorable current profile based on its improving earnings outlook and more attractive valuation.

Key Decisions for Investors

• Investors evaluating AI-driven drug discovery stocks may find Recursion Pharmaceuticals (RXRX) a more compelling opportunity at its current valuation, considering its narrowing loss estimates, recent positive preliminary clinical data for REC-4881, and significant year-to-date stock underperformance which could offer rebound potential.
• Caution is warranted for Schrodinger (SDGR) due to its elevated valuation metrics, particularly a price-to-book ratio above its historical average, coupled with analyst expectations of widening losses per share in 2025, despite its strong Q1 revenue growth and upcoming clinical readouts.
• Key upcoming catalysts to monitor closely include further clinical data from RXRX's TUPELO study (REC-4881) in the second half of 2025 and its DAHLIA study (REC-1245) in the first half of 2026, as well as initial results from SDGR's SGR-1505 trial expected in June 2025, and SGR-2921 and SGR-3515 trials in the second half of 2025.